First Author | Matsuda J | Year | 2009 |
Journal | Biochem Biophys Res Commun | Volume | 382 |
Issue | 1 | Pages | 149-52 |
PubMed ID | 19265678 | Mgi Jnum | J:147376 |
Mgi Id | MGI:3840403 | Doi | 10.1016/j.bbrc.2009.02.153 |
Citation | Matsuda J, et al. (2009) Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 382(1):149-52 |
abstractText | For the development of a safe vaccine for Alzheimer's disease (AD), we studied the immunogenicity of amyloid beta (Abeta) peptides without adjuvant. Addition of a cysteine residue (Cys) to Abeta peptides enhanced immunogenicity in mice compared to those without Cys. Vaccination with the Abeta-Cys peptides reduced Abeta deposits in AD model mice. From these results, the Abeta-Cys peptides, administered without adjuvant, are considered candidates for vaccine therapy for AD. |